Generative AI boosts life sciences drug discovery

AI is not replacing clinical research jobs. Instead, it is rapidly redefining them, and the shift is already visible. What’s changing: 1. Fewer repetitive tasks Routine tasks are being automated, resulting in a reduced need for execution-heavy work. 2. Jobs are evolving, not disappearing Most roles are only partially impacted by AI, rather than being fully replaced. 3. Smaller, more efficient teams Sponsors and CROs are transitioning to leaner teams that are supported by technology. 4. New expectations for talent Clinical professionals are now expected to work with digital tools, data, and AI systems. 5. The real shift: augmentation AI is amplifying human expertise, not replacing it. The takeaway: The future of clinical research isn’t about fewer jobs; it’s about different jobs with higher expectations. Curious to hear your perspective: How is AI changing roles in your clinical teams today #clinicalresearch #CRO #biotech #pharma #AI #digitalhealth #clinicaltrials #futureofwork #innovation

AI in Life Sciences: The Opportunity and the Responsibility The data is showing AI in healthcare is delivering measurable returns — accelerating drug discovery, automating clinical workflows, transforming diagnostics. But here's what I think matters more than the ROI numbers: AI works best when it augments human expertise, not replaces it. We call it our 'Human in the Loop.' The breakthrough moments in biotech don't happen because AI runs faster — they happen because researchers, clinicians, and regulators can actually trust the system. That requires: • Transparency — open audit, interpretable reasoning you can challenge • Accountability — clear ownership back to researchers when AI guides a decision • Guardrails — designed constraints that protect and accelerate approval pathways I've watched innovations fail not from weak science, but from broken coordination. AI can fix that — if we build it right. The companies winning at this aren't the ones with the fanciest algorithms or the best marketing. They're the ones building infrastructure that earned trust through clarity, rigor, audit, security, and human-centered design and decision. #AI #LifeSciences #Leadership #HumanInTheLoop #HealthInnovation #Responsibility #MPHNexora

The Biggest Bottleneck in AI Drug Discovery Is... I’ve been asking this question to every pharma team I consult with: “What’s your biggest bottleneck in adopting AI for drug discovery?” The top 5 answers: 1. DATA QUALITY (not quantity) : “We have millions of data points, but 80% is noisy or inconsistent.” 2. INTEGRATION with existing workflows : “The AI model works great in isolation but doesn’t fit our pipeline.” 3. TRUST / INTERPRETABILITY : “The model says this compound is good, but WHY?” 4. TALENT GAP : “We can’t find people who understand BOTH AI and chemistry.” 5. VALIDATION : “How do we know the AI prediction is reliable enough to bet millions on?” Notice something? None of these are algorithmic problems. They’re people, process, and data problems. This is exactly why consultancy matters in AIDD. It’s not about building the fanciest model. It’s about making it WORK in the real world. Which bottleneck resonates most with you? Comment below! #AIDD #DrugDiscovery #DataScience #Pharma #Consulting #CADD

A couple of years ago, one thing really stood out to me: there was a noticeable gap between medical, pharma organizations and modern technology—especially AI. It honestly surprised me. In an industry built on innovation, discovery, and scientific rigor, I expected to see well-established structures around technology—similar to traditional R&D departments. But instead, AI and advanced analytics often felt fragmented, scattered across teams rather than centralized and strategically driven. If you think about it, pharma already has a proven model for innovation: R&D. So why not apply a similar structure to AI? Imagine dedicated AI-focused “R&D-like” AI groups: • Drug discovery & modeling • Data infrastructure & engineering • Commercial Enablement, • Medical enablement, • AI safety, ethics, governance, and compliance. These wouldn’t replace teams—they would enable them, create standards, and drive alignment. One of the simplest gaps? Not enough technical talent embedded within teams. Many teams want to use AI, but without data scientists and engineers working alongside them, leading AI enablement, progress slows. This is one of the fastest gaps to fix. Encouragingly, leaders are recognizing this urgency. Pfizer’s CEO Albert Bourla, has emphasized the importance of scaling the use of artificial intelligence across the organization—a clear signal that AI is becoming foundational, not optional. We’ve seen this before. When the internet evolved, companies built IT departments and standardized systems. Today, that’s a given. AI is at the same inflection point. Just like communication technologies rely on shared protocols (internet, Bluetooth), organizations need common standards for AI. You can say different things—but you need the same language. The companies that close this gap—by combining structure, embedded expertise, and clear governance—will lead. Because the goal isn’t just experimenting with AI… It’s operationalizing it at scale. #MedicalAffairs #Pharma #DrugDiscovery #AIinHealthcare #DataGovernance #AIEthics #ArtificialIntelligence #AIAdoption #TechInPharma #EnterpriseAI

AI is no longer just optimizing workflows — it’s rewriting the future of medicine. In the last few years, we’ve seen breakthroughs that would have taken decades… compressed into months: 🧬 AI models identifying new drug candidates in record time 🧪 Protein folding solved at scale, unlocking how diseases actually behave 💊 Personalized treatments tailored to your exact genetic makeup 🦠 Early detection of cancers and rare diseases before symptoms even appear What’s powerful isn’t just speed — it’s possibility. We’re moving from reactive healthcare → to predictive, preventative, and precision medicine. Imagine a world where: Diseases are detected before they develop Drug discovery is measured in weeks, not years Treatment plans are unique to every individual This isn’t theory anymore. It’s happening. But with this acceleration comes responsibility: ⚖️ Ethical use of data 🔐 Patient privacy 🌍 Equitable access to these advancements AI won’t replace doctors — but doctors empowered by AI will redefine healthcare. The real breakthrough? Not just curing disease… but fundamentally changing how we understand it. #AI #Healthcare #Innovation #MedicalBreakthroughs #FutureOfMedicine #DigitalTransformation Nihka Technology Group

🧬 AI is reshaping biotech — faster, smarter, and more precise than ever. From drug discovery and protein structure prediction to clinical trial optimisation and personalised medicine, AI is rapidly becoming a core capability within the biotech sector—not just a nice-to-have. What’s changed recently isn’t just computing power, but confidence. We’re seeing AI move beyond experimentation into real-world impact. 🌍 The most exciting part? The convergence of biological insight + high‑quality data + responsible AI. When domain expertise leads the tech—not the other way around—we unlock innovation that directly benefits patients. 🫶 The organisations that will win aren’t simply “using AI”, but embedding it thoughtfully, investing in talent, data foundations, and ethics from day one. Biotech is entering its next era—and AI is one of its most powerful catalysts. 🚀 #Biotech #ArtificialIntelligence #AIinBiotech #LifeSciences #DrugDiscovery #HealthTech #Innovation #hexartalent

Hot take: AI isn’t “coming” to life sciences. It’s already in the lab… quietly judging your experimental design. I’ve done the full loop: academia → big data → back again (because clearly I enjoy complex systems with unclear documentation). And for quite a while now, Jasmine Willis and I have watched pharma “innovate”… while still treating PDFs like a premium technology. So what’s actually happening right now: - AI is redesigning drug discovery Not just faster pipelines: completely new ways of thinking about molecules, targets, and probability. - AI has made its way into quality assurance Less checkbox theatre, more actual signal detection. (Finally!!!) - AI is taking over medical writing & regulatory Yes, even the documents nobody enjoys writing. Or... especially those. Here’s the part most people don’t want to admit: You can build the most powerful AI tool in the world… If scientists hate using it, congratulations: you’ve built a very expensive paperweight. UX and human behavior > model performance. Every time. The uncomfortable truth? AI won’t replace scientists. But scientists who understand AI will replace those who don’t. And nope... adding “AI-powered” to your slide deck is not a strategy. If you’re in life sciences or pharma and still treating AI like a side project, I’m curious: What’s actually blocking adoption in your organisation? Also, slightly selfish agenda here: I want to build a community around AI in life sciences. Less buzzwords, more real exchange on what actually works (and what fails spectacularly). If that resonates, let’s connect. (And if your answer is “compliance”… we definitely need to talk.) #AI #LifeSciences #Pharma #DigitalHealth #MachineLearning #Innovation Jasmine Willis Joel Henry Philipp Osterwalder Yannick Misteli Matthias Hess Juan Antonio Madrigal Luise Wolf Anabelle S. Valeriy Ovchinskiy, PhD. Gopika Venu Nair Cathelijne van der Wouden Bernhard M. Ahmed Fathy Julian 🧬 West

Everyone is excited about AI in Life Sciences. But very few talk about why it’s so hard to build. As a Product Manager working closely with data, compliance, and clinical workflows, I’ve realized this: AI in life sciences isn’t a tech problem. It’s a trust problem. Here are 5 real challenges we face 👇 🔹 1. Data ≠ Usable Data Healthcare data is fragmented, noisy, and often locked in silos. EHRs, lab reports, imaging none of it speaks the same language. 🔹 2. Regulation Slows Everything Down (for good reason) You’re not just shipping features you’re navigating FDA, HIPAA, and ethical boundaries. Speed takes a backseat to safety. 🔹 3. Model Accuracy Isn’t Enough Even a 95% accurate model can fail in real-world clinical settings. Context matters more than precision metrics. 🔹 4. Explainability is Non-Negotiable Doctors won’t trust a “black box.” If your AI can’t explain why, it won’t be used no matter how good it is. 🔹 5. Human-in-the-Loop is Mandatory AI doesn’t replace clinicians it augments them. Designing that collaboration is where product thinking really matters. 💡 The real opportunity? Building AI products that balance innovation with empathy, compliance, and trust. Because in life sciences, you’re not just building products… You’re impacting lives. Curious to hear from others: What’s the hardest part of building AI in healthcare/life sciences from your experience? #ProductManagement #AI #LifeSciences #HealthTech #AIProducts #DigitalHealth #ProductLeadership

Across many industries today, companies are trying to reduce costs by replacing parts of the workforce with AI. Regulatory Affairs will not be immune to this pressure. As organizations look for efficiency, AI will increasingly be used to automate operational tasks such as document searches, literature reviews, or navigating guidance across different regions. However, Regulatory Affairs is not only about accessing information. Much of the work involves interpreting incomplete data, understanding regulatory expectations, and making strategic decisions in highly specific product contexts. Each product has its own scientific, clinical, and regulatory story, and translating that into a viable regulatory pathway still relies heavily on human judgment and experience. AI will undoubtedly become a powerful tool in the regulatory toolbox, helping professionals work faster and manage growing volumes of information. But strategy, risk assessment, and negotiation with authorities remain areas where human expertise is essential. The real transformation in Regulatory Affairs will likely come not from replacing professionals with AI, but from professionals who know how to use AI effectively. #RegulatoryAffairs #AI #ArtificialIntelligence #PharmaIndustry #Biotech #MedTech #LifeSciences #DrugDevelopment #RegulatoryStrategy #FutureOfWork

AI is transforming healthcare. From diagnosis to drug discovery. Our role: • Medical data annotation • Image labeling • Data processing • Quality validation • AI support 👉 Better data leads to better outcomes. We are proud to support innovations that can save lives. #Healthcare #AI